CytoMed Therapeutics Limited
CytoMed Therapeutics Limited (GDTC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gdtc · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CytoMed Therapeutics Limited (GDTC) measures how much investors pay for each dollar of the company's trailing earnings. GDTC's current PE ratio of N/A is calculated by dividing its stock price of $1.06 by its TTM earnings per share of -$0.46.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CytoMed Therapeutics LimitedYou GDTC | $13M | N/A | — | -$0.46 |
 CollPlant Biotechnologies Ltd. CLGN | $5M | N/A | — | -$0.94 |
 Enlivex Therapeutics Ltd. ENLV | $18M | 0.03x | — | $27.04 |
 Lisata Therapeutics, Inc. LSTA | $31M | N/A | — | -$1.91 |
 MetaVia Inc. MTVA | $4M | N/A | — | -$7.35 |
 NuCana plc NCNA | $13M | N/A | — | -$7.94 |
 NeuroSense Therapeutics Ltd. NRSN | $19M | N/A | — | -$0.44 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.34 | — | |
2024-12-31 FY2024 | — | $-0.22 | — | |
2023-12-31 FY2023 | — | $-0.39 | — | |
2022-12-31 FY2022 | — | $-0.39 | — | |
2021-12-31 FY2021 | — | $-0.30 | — | |
2020-12-31 FY2020 | — | $-0.33 | — | |
2019-12-31 FY2019 | — | $-0.15 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CytoMed Therapeutics Limited (GDTC) measures how much investors pay for each dollar of the company's trailing earnings. GDTC's current PE ratio of N/A is calculated by dividing its stock price of $1.06 by its TTM earnings per share of -$0.46.
Frequently asked questions
GDTC pe ratio · 6 questionsGDTC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.06 and TTM EPS of -$0.46. Data sourced from Financial Modeling Prep via GDTC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CytoMed Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09